孟鲁司特治疗咳嗽变异性哮喘的疗效及预防复发作用

目的：探讨孟鲁司特治疗咳嗽变异性哮喘的疗效及预防复发作用.方法：选择咳嗽变异性哮喘患者72例,随机分为两组（观察组和对照组）.两组患者均予沙美特罗/氟替卡松粉吸入剂1吸,bid,咳嗽症状消失后停用.对照组加用酮替芬片1 mg,po,bid,连用12周;观察组加用孟鲁司特咀嚼片10 mg,po,qd,连用12周.观察并比较两组患者治疗后临床疗效及不良反应情况,对治疗有效者继续随访1年,比较复发率及典型哮喘的转化率.结果：治疗12周后,观察组的临床总有效率94.44%,明显高于对照组（P＜0.05）.对照组和观察组治疗中分别出现药物不良反应6例和4例,症状均较轻,无严重的药物不良反应发生.两组不良反应发生率比较差异无统计学意义（P＞0.05）.随访1年,观察组患者复发率及典型哮喘的转化率均明显低于对照组（P＜0.05）.结论：孟鲁司特治疗咳嗽变异性哮喘具有较好的疗效,安全性较佳,能明显降低复发率及典型哮喘的转化率,具有治疗和预防其复发作用.

Curative and Recurrence Preventive Effect of Montelukast on Cough Variant Asthma

Objective： To investigate the curative effect and recurrence preventive function of montelukast on cough variant asth- ma. Methods： Totally 72 patients with cough variant asthma were selected and divided into the experimental group and the control group randomly. The patients in the two groups were inhaled salmeteroL/acid fluticasone propionate one suck per time, twice a day, till cough symptom was disappeared. The patients in the control group were additionally orally given 1 mg ketotifen fumarate tablets twice a day for 12 weeks. The patients in the experimental group were additionally orally given 10rag montelukast chewable tablets once a day for 12 weeks. The clinical curative effect and adverse reactions in the two groups were observed and compared, the reoccurrence rate and conversion rate of typical asthma after the medical treatment in one year were followed up and observed as well. Results： After the 12-week medical treatment, the total clinical efficiency in the experimental group （94.44%） was much higher than that in the control group （77.78% ~ （ P 〈 0.05 ）. Totally 6 and 4 cases of drug adverse reaction （ADR） were appeared in the control group and the ex- perimental group, respectively with mild symptom. The ADR occurrence rate in the two groups showed no obvious statistical difference （P 〉 0.05 ）. After one-year follow-up, the reoccurrence rate and conversion rate of typical asthma in the experimental group （29.41%） and （23.53%） ] were much lower than those in the control group （57.14%） and （50.00%） ] （P 〈 0. 05 ）. Conclu- sion： Montelukast has reliable curative effect on cough variant asthma with high safety, and can obviously reduce the Occurrence rate and conversion rate of typical asthma, suggesting the treatment and reoccurrence preventive function.